Your browser is no longer supported. Please, upgrade your browser.
NKTR Nektar Therapeutics weekly Stock Chart
NKTR [NASD]
Nektar Therapeutics
IndexS&P 500 P/E- EPS (ttm)-2.43 Insider Own0.60% Shs Outstand176.14M Perf Week-9.23%
Market Cap3.01B Forward P/E- EPS next Y-2.70 Insider Trans-30.53% Shs Float174.01M Perf Month-47.09%
Income-422.70M PEG- EPS next Q-0.75 Inst Own96.18% Short Float13.05% Perf Quarter-48.80%
Sales119.10M P/S25.30 EPS this Y289.50% Inst Trans13.52% Short Ratio10.28 Perf Half Y-60.24%
Book/sh8.92 P/B1.92 EPS next Y7.80% ROA-19.50% Target Price44.92 Perf Year-71.50%
Cash/sh8.60 P/C1.99 EPS next 5Y-7.30% ROE-25.20% 52W Range17.30 - 69.76 Perf YTD-47.95%
Dividend- P/FCF- EPS past 5Y36.30% ROI34.90% 52W High-75.47% Beta2.74
Dividend %- Quick Ratio14.00 Sales past 5Y51.60% Gross Margin80.90% 52W Low-1.10% ATR1.73
Employees618 Current Ratio14.10 Sales Q/Q-97.90% Oper. Margin- RSI (14)18.67 Volatility5.35% 6.38%
OptionableYes Debt/Eq0.00 EPS Q/Q-111.80% Profit Margin- Rel Volume1.67 Prev Close17.87
ShortableYes LT Debt/Eq0.16 EarningsAug 08 AMC Payout- Avg Volume2.21M Price17.11
Recom2.20 SMA20-34.42% SMA50-44.60% SMA200-51.46% Volume3,644,462 Change-4.25%
Aug-09-19Downgrade Mizuho Buy → Neutral $79 → $21
Aug-09-19Downgrade JP Morgan Overweight → Neutral $62 → $33
Aug-09-19Downgrade Jefferies Buy → Hold $59 → $23
Mar-15-19Initiated SVB Leerink Mkt Perform $38
Dec-13-18Initiated Goldman Buy $62
Jun-11-18Downgrade H.C. Wainwright Buy → Neutral $54
Jun-04-18Reiterated H.C. Wainwright Buy $125 → $97
Apr-20-18Initiated Seaport Global Securities Buy $120
Apr-13-18Resumed Piper Jaffray Overweight $125
Apr-06-18Reiterated Mizuho Buy $89 → $103
Apr-02-18Resumed H.C. Wainwright Buy $125
Mar-02-18Reiterated Canaccord Genuity Buy $80 → $94
Jan-22-18Reiterated Mizuho Buy $45 → $89
Nov-13-17Reiterated Mizuho Buy $30 → $45
Nov-13-17Reiterated Canaccord Genuity Buy $35 → $50
Nov-09-17Initiated Canaccord Genuity Buy $35
Aug-17-17Initiated Evercore ISI In-line $20
Aug-07-17Initiated H.C. Wainwright Buy $31
Mar-20-17Reiterated ROTH Capital Buy $23 → $31
Nov-08-16Initiated Aegis Capital Buy
Aug-20-19 08:00PM  Bragar Eagel & Squire, P.C. Announces That a Class Action Lawsuit Has Been Filed Against Nektar Therapeutics, Inc. (NASDAQ: NKTR) and Encourages Nektar Investors to Contact the Firm PR Newswire
01:31PM  INVESTOR ALERT: Law Offices of Howard G. Smith Announces the Filing of a Securities Class Action on Behalf of Nektar Therapeutics Investors (NKTR) Business Wire
Aug-19-19 09:43PM  Glancy Prongay & Murray LLP Files a Securities Class Action on Behalf of Nektar Therapeutics Investors (NKTR) Business Wire
Aug-15-19 08:35PM  Bragar Eagel & Squire, P.C. is Investigating Nektar Therapeutics, Inc. (NASDAQ: NKTR) on Behalf of Stockholders and Encourages Nektar Investors to Contact the Firm PR Newswire
05:22AM  Edited Transcript of NKTR earnings conference call or presentation 8-Aug-19 9:00pm GMT Thomson Reuters StreetEvents
Aug-14-19 10:00AM  Bronstein, Gewirtz & Grossman, LLC Announces Investigation of Nektar Therapeutics (NKTR) PR Newswire
Aug-13-19 03:06PM  INVESTIGATION REMINDER: The Schall Law Firm Announces it is Investigating Claims Against Nektar Therapeutics and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm Business Wire
10:44AM  Bronstein, Gewirtz & Grossman, LLC Announces Investigation of Nektar Therapeutics (NKTR) ACCESSWIRE
Aug-12-19 02:20PM  Nektar Erases $1.8 Billion of Value on Doubts Over Its Cancer Drug Bloomberg -11.19%
12:29PM  Why Nektar Therapeutics Stock Is Falling Again Today Motley Fool
09:30AM  Nektar Therapeutics Drops Sharply for Second Day After Admitting Batch Issues TheStreet.com
08:23AM  3 Big Stock Charts for Monday: Xilinx, News Corp and Gilead Sciences InvestorPlace
Aug-10-19 01:33PM  INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Nektar Therapeutics and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm Business Wire
Aug-09-19 06:30PM  Glancy Prongay & Murray LLP Announces Investigation on Behalf of Nektar Therapeutics Investors Business Wire -29.25%
04:35PM  Why Farfetch, Waitr Holdings, and Nektar Therapeutics Slumped Today Motley Fool
04:17PM  Biotech Crashes 29% After Bad Drug Likely Skewed Cancer Tests Investor's Business Daily
03:44PM  INVESTOR ALERT: Law Offices of Howard G. Smith Announces Investigation on Behalf of Nektar Therapeutics Investors Business Wire
03:13PM  Pharma companies Amarin, Nektar Therapeutics nosedive on product concerns Yahoo Finance Video
02:03PM  Large Option Trader Buying Nektar Calls Following Stock Crash Benzinga
01:33PM  Drugmakers Put Bad Spin on a Bizarre Week Bloomberg
12:56PM  Why Nektar Therapeutics Stock Is Crashing Today Motley Fool
11:58AM  Investor Alert: Ademi & O'Reilly, LLP Investigates Possible Securities Fraud of Nektar Therapeutics PR Newswire
11:39AM  Biotech Investors Jolted Out of Summer Lull as High-Fliers Sink Bloomberg
11:11AM  Nektar (NKTR) Q2 Earnings Beat Estimates, Revenues Miss Zacks
08:59AM  Nektar Therapeutics Stock Is Plunging Because Theres No Shortage of Bad News Barrons.com
07:28AM  Nektar Therapeutics Sinks on Cancer Treatment Manufacturing Issues TheStreet.com
07:19AM  The Daily Biotech Pulse: Vascepa Delay Sends Amarin Reeling, Eidos Jumps On Buyout Offer, Nektar's Bitter Q2 Benzinga
06:00AM  What You'll Want to Know About Nektar Therapeutics' Q2 Results Motley Fool
Aug-08-19 10:24PM  Nektar Therapeutics (NKTR) Q2 2019 Earnings Call Transcript Motley Fool
06:37PM  Nektar Therapeutics stock drops after results MarketWatch
06:11PM  Another Biotech Stock Halted As Manufacturing Issue Comes To Light Investor's Business Daily
05:45PM  Nektar Therapeutics (NKTR) Reports Q2 Loss, Misses Revenue Estimates Zacks
04:15PM  Nektar Therapeutics Reports Financial Results for the Second Quarter of 2019 PR Newswire
Aug-07-19 08:34AM  Should You Buy Nektar (NKTR) Ahead of Earnings? Zacks
Aug-06-19 08:00AM  Analysts: These 12 S&P 500 Stocks Are The Biggest Bargains Now Investor's Business Daily
Aug-05-19 01:41PM  Here's Why Nektar Therapeutics Declined 20% in July Motley Fool -7.37%
Aug-01-19 10:33AM  Nektar Therapeutics (NKTR) Expected to Beat Earnings Estimates: Should You Buy? Zacks +9.59%
08:54AM  Is a Beat in Store for Nektar (NKTR) This Earnings Season? Zacks
07:00AM  Nektar Therapeutics and Bristol-Myers Squibb Announce U.S. FDA Breakthrough Therapy Designation for Bempegaldesleukin (NKTR-214) in Combination with Opdivo® (nivolumab) for the Treatment of Patients with Untreated Advanced Melanoma PR Newswire
Jul-30-19 05:40PM  Big drugmakers trade Peninsula plant as part of larger deal American City Business Journals
05:00PM  Nektar to Announce Financial Results for the Second Quarter 2019 on Thursday, August 8, 2019, After Close of U.S.-Based Financial Markets PR Newswire
11:53AM  Can GW Pharmaceuticals (GWPH) Deliver a Beat in Q2 Earnings? Zacks
11:31AM  CannTrust (CTST) to Report Q2 Earnings: What's in Store? Zacks
Jul-25-19 10:15PM  Nektar Therapeutics Inc (NKTR) President & CEO Howard W Robin Sold $3.1 million of Shares GuruFocus.com -6.63%
03:47PM  Here's Why Nektar Therapeutics Fell as Much as 10.8% Today Motley Fool
Jul-22-19 02:16PM  How Much Did Nektar Therapeutics's (NASDAQ:NKTR) CEO Pocket Last Year? Simply Wall St.
Jul-15-19 12:44PM  Nektar Therapeutics Stock Poised for Significant Move Investopedia
Jul-12-19 08:15PM  Nektar Therapeutics Inc (NKTR) SVP & CFO Gil M Labrucherie Sold $864,250 of Shares GuruFocus.com
Jul-08-19 06:46PM  Here's Why Nektar Therapeutics Stock Gained 13.6% in June Motley Fool
Jun-23-19 04:42PM  Is Nektar Therapeutics (NKTR) A Good Stock To Buy? Insider Monkey
Jun-21-19 06:00AM  Nektar's Drug Could be a "Big Deal" MoneyShow
Jun-19-19 01:58PM  Harry Boxers three biotech stocks on the move include Nektar Therapeutics MarketWatch
Jun-14-19 12:42PM  Should We Be Delighted With Nektar Therapeutics's (NASDAQ:NKTR) ROE Of 40%? Simply Wall St.
07:22AM  3 Big Stock Charts for Friday: Symantec, Vertex Pharmaceuticals and Nektar Therapeutics InvestorPlace
Jun-13-19 07:44AM  The Daily Biotech Pulse: Savara Slumps On Flunked Trial, NuCana Takes Off, Tetraphase Downsizes Benzinga
06:45AM  First-in-Human Data Presented from Phase 1a Study of NKTR-358, a Novel T Regulatory Cell Stimulator, at Annual European Congress of Rheumatology PR Newswire
Jun-11-19 12:50PM  Edited Transcript of NKTR earnings conference call or presentation 8-May-19 9:00pm GMT Thomson Reuters StreetEvents
09:00AM  Nektar Therapeutics to Host Webcast Conference Call with Immunology Expert for Analysts & Investors During 2019 European Congress of Rheumatology (EULAR 2019) PR Newswire
07:00AM  Is iShares MSCI USA Equal Weighted ETF (EUSA) a Strong ETF Right Now? Zacks
Jun-08-19 04:09PM  The Week Ahead In Biotech: Conferences, PDUFA Dates And Clinical Trial Readouts Benzinga
Jun-07-19 09:30AM  Nektar (NKTR) Down 7% Since Last Earnings Report: Can It Rebound? Zacks
Jun-05-19 03:11PM  Cancer-Fighting Stocks & ETF: What You Need to Know Zacks
Jun-04-19 08:39AM  Nektar (NKTR) in Focus: Stock Moves 8.8% Higher Zacks
Jun-03-19 04:31PM  Why El Paso Electric, Nektar Therapeutics, and Hecla Mining Jumped Today Motley Fool +8.75%
04:24PM  Who Are The Winners And Losers From The Year's Biggest Cancer Meeting? Investor's Business Daily
02:46PM  Why Cancer-Fighting Stocks & ETFs Are Soaring Zacks
12:41PM  Nektar Therapeutics Jumps on Positive Results From Melanoma Treatment Study TheStreet.com
Jun-01-19 09:00AM  Nektar Therapeutics Presents Biomarker and Clinical Data from PIVOT-02 Phase 2 Study of Bempegaldesleukin with Nivolumab at 2019 ASCO Annual Meeting PR Newswire
May-31-19 03:45PM  How To Know Whats In Your ETF ETF.com
08:57AM  These 6 stocks in the S&P 500 are down at least 50% and analysts say buy MarketWatch
May-25-19 10:19AM  What Is Nektar Therapeutics' New Game Plan? Motley Fool
May-24-19 09:56AM  Nektar (NKTR) Announces Formation of CNS-Focused Subsidiary Zacks
May-23-19 05:29PM  Why this pain-killing opioid is spinning into a new company American City Business Journals
08:00AM  Nektar Announces the Launch of Inheris Biopharma, Inc. PR Newswire
May-22-19 07:29AM  Jim Cramer Weighs In On Nektar, L Brands And More Benzinga
May-21-19 07:06PM  Cramer's lightning round: McDonald's is 'one of the greatest stocks of our time' CNBC
May-16-19 04:07PM  6 Positions the Vanguard Health Care Fund Continues to Increase GuruFocus.com -7.55%
May-15-19 05:00PM  Nektar Therapeutics Announces Five Accepted Abstracts at 2019 American Society of Clinical Oncology's (ASCO) Annual Meeting PR Newswire
May-10-19 09:55AM  3 Small Drug Stocks Poised to Beat Q1 Earnings Estimates Zacks
May-09-19 04:08PM  This Biotech Stock Is Flying As Cancer Update, Opioid Approval Loom Investor's Business Daily +7.49%
02:33PM  Nektar (NKTR) Q1 Earnings & Revenues Beat, Decline Y/Y Zacks
07:00AM  What You'll Want to Know About Nektar Therapeutics' Q1 Earnings Results Motley Fool
12:23AM  Nektar Therapeutics (NKTR) Q1 2019 Earnings Call Transcript Motley Fool
May-08-19 05:45PM  Nektar Therapeutics (NKTR) Reports Q1 Loss, Tops Revenue Estimates Zacks
04:35PM  Nektar: 1Q Earnings Snapshot Associated Press
04:10PM  Nektar Therapeutics Reports Financial Results for the First Quarter of 2019 PR Newswire
May-07-19 03:31PM  Nektar Therapeutics Expected to Lose 69 Cents a Share TheStreet.com
09:35AM  What's in the Cards for Nektar (NKTR) This Earnings Season? Zacks
May-02-19 10:33AM  Earnings Preview: Nektar Therapeutics (NKTR) Q1 Earnings Expected to Decline Zacks
May-01-19 05:00PM  Nektar to Announce Financial Results for the First Quarter 2019 on Wednesday, May 8, 2019, After Close of U.S.-Based Financial Markets PR Newswire
Apr-28-19 05:00PM  3 Top Biotech Stocks to Buy Right Now Motley Fool
Apr-24-19 02:55PM  S&P 500 closes at record high, even as EPS growth stagnates Reuters
Apr-23-19 06:56PM  S&P 500 closes at record high, even as EPS growth stagnates Reuters
Apr-22-19 10:42AM  Were Hedge Funds Right About Souring On Nektar Therapeutics (NKTR)? Insider Monkey
Apr-12-19 03:26PM  These 3 Falling Knives Are Expected to Outperform GuruFocus.com
Apr-11-19 10:57AM  Analysts believe the stock market will set a record soon and these names are going to lead the way CNBC
Apr-03-19 04:38PM  GameStop falls while Dave & Buster's and Blue Apron rise Associated Press
11:50AM  A Look At Nektar Therapeutics's (NASDAQ:NKTR) Exceptional Fundamentals Simply Wall St.
Apr-02-19 03:00PM  Nektar Therapeutics Presents Preclinical Data on its Immuno-Oncology Pipeline Candidates at the American Association for Cancer Research (AACR) Annual Meeting 2019 PR Newswire
07:30AM  The Daily Biotech Pulse: FDA Nod For ADMA, Regulatory Setback For Apyx, Achieve Life Sciences Smoking Cessation Drug Trial Benzinga
Nektar Therapeutics develops drug candidates for cancer, auto-immune disease, and chronic pain in the United States. The company develops NKTR-181, an orally-available mu-opioid analgesic molecule, which is in Phase III clinical trial for moderate to severe chronic pain; ONZEALD, a topoisomerase I inhibitor that is in Phase III clinical trial for advanced metastatic breast cancer in patients with brain metastases; and NKTR-214, a CD122-preferential interleukin-2 (IL-2) pathway agonist, which is in Phase I to treat immuno-oncology. It also develops NKTR-358, cytokine Treg stimulant, which is in Phase I to treat autoimmune diseases; NKTR-262, a toll-like receptor agonist that is in Phase I for solid tumors; and NKTR-255, which is in preclinical stage for immuno-oncology. In addition, the is developing ADYNOVATE and ADYNOVI for hemophilia A; MOVANTIK for opioid-induced constipation in adult patients with chronic non-cancer pain; CIMZIA for crohn's disease, rheumatoid arthritis, and psoriasis/ankylosing spondylitis; and MIRCERA for anemia associated with chronic kidney disease. Further, it is developing Macugen for age-related macular degeneration; Somavert for acromegaly; Neulasta for neutropenia; Dapirolizumab Pegol for systemic lupus erythematosus; PEGPH20 for pancreatic, non-small cell lung cancer, and other tumor types; and longer-acting blood clotting proteins for hemophilia. The company has collaboration agreement with Takeda Pharmaceutical Company Ltd.; AstraZeneca AB; UCB Pharma S.A.; F. Hoffmann-La Roche Ltd; Bausch Health Companies Inc.; Pfizer Inc.; Amgen Inc.; UCB Pharma (Biogen); Halozyme Therapeutics, Inc.; Bristol-Myers Squibb Company; Baxalta Incorporated; and Eli Lilly and Company, as well as with Merck KGaA and Pfizer Inc. Nektar Therapeutics also has a research collaboration with Trovagene, Inc. for the treatment of metastatic colorectal cancer. Nektar Therapeutics was founded in 1990 and is headquartered in San Francisco, California.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Thomsen Jillian B.SVP & Chief Accounting OfficerAug 16Sale18.151,80932,833163,154Aug 19 07:09 PM
ROBIN HOWARD WPresident & CEOAug 16Sale18.1512,551227,801282,775Aug 19 07:08 PM
Labrucherie Gil MSVP & Chief Financial OfficerAug 16Sale18.155,06391,893122,872Aug 19 07:07 PM
Nicholson JohnSVP & Chief Operating OfficerAug 16Sale18.153,81969,315162,759Aug 19 07:07 PM
Doberstein Stephen KSVP & Chief Scientific OfficerAug 16Sale18.153,24558,89792,668Aug 19 07:06 PM
Labrucherie Gil MSVP & Chief Financial OfficerAug 14Option Exercise7.2125,000180,250152,935Aug 16 08:13 PM
Labrucherie Gil MSVP & Chief Financial OfficerAug 14Sale17.7925,000444,750127,935Aug 16 08:13 PM
ROBIN HOWARD WPresident & CEOJul 25Option Exercise7.2133,333240,331328,659Jul 25 08:02 PM
ROBIN HOWARD WPresident & CEOJul 25Sale29.6533,333988,323295,326Jul 25 08:02 PM
ROBIN HOWARD WPresident & CEOJul 24Option Exercise7.2133,334240,338328,660Jul 25 08:02 PM
ROBIN HOWARD WPresident & CEOJul 24Sale32.1133,3341,070,355295,326Jul 25 08:02 PM
ROBIN HOWARD WPresident & CEOJul 23Option Exercise7.2133,333240,331328,659Jul 25 08:02 PM
ROBIN HOWARD WPresident & CEOJul 23Sale32.1033,3331,069,989295,326Jul 25 08:02 PM
Labrucherie Gil MSVP & Chief Financial OfficerJul 10Option Exercise7.2125,000180,250152,935Jul 12 06:31 PM
Labrucherie Gil MSVP & Chief Financial OfficerJul 10Sale34.5725,000864,250127,935Jul 12 06:31 PM
Lingnau LutzDirectorJul 08Option Exercise9.2410,00092,40033,200Jul 10 05:34 PM
Lingnau LutzDirectorJul 08Sale34.6310,000346,30023,200Jul 10 05:34 PM
Labrucherie Gil MSVP & Chief Financial OfficerJun 17Option Exercise7.2125,000180,250152,935Jun 19 05:50 PM
Labrucherie Gil MSVP & Chief Financial OfficerJun 17Sale33.7125,000842,750127,935Jun 19 05:50 PM
ROBIN HOWARD WPresident & CEOMay 23Option Exercise7.2133,333240,331328,659May 23 07:19 PM
ROBIN HOWARD WPresident & CEOMay 23Sale32.6933,3331,089,656295,326May 23 07:19 PM
ROBIN HOWARD WPresident & CEOMay 22Option Exercise7.2133,334240,338328,660May 23 07:19 PM
ROBIN HOWARD WPresident & CEOMay 22Sale33.3833,3341,112,689295,326May 23 07:19 PM
ROBIN HOWARD WPresident & CEOMay 21Option Exercise7.2133,333240,331328,659May 23 07:19 PM
ROBIN HOWARD WPresident & CEOMay 21Sale32.9333,3331,097,656295,326May 23 07:19 PM
Thomsen Jillian B.SVP & Chief Accounting OfficerMay 16Sale31.371,92860,481164,463May 17 08:22 PM
ROBIN HOWARD WPresident & CEOMay 16Sale31.3713,383419,825295,326May 17 08:22 PM
Labrucherie Gil MSVP & Chief Financial OfficerMay 16Sale31.373,767118,171127,935May 17 08:20 PM
Nicholson JohnSVP & Chief Operating OfficerMay 16Sale31.374,077127,895166,578May 17 08:21 PM
Hora ManinderSVP Pharma Dev & Mfg OpsMay 16Sale31.372,44976,82594,694May 17 08:19 PM
Doberstein Stephen KSVP & Chief Scientific OfficerMay 16Sale31.373,461108,57295,913May 17 08:18 PM
GREER R SCOTTDirectorMar 08Option Exercise5.1410,00051,400145,083Mar 12 06:18 PM
ROBIN HOWARD WPresident & CEOFeb 21Option Exercise7.2133,333240,331342,042Feb 21 08:16 PM
ROBIN HOWARD WPresident & CEOFeb 21Sale41.0133,3331,366,986308,709Feb 21 08:16 PM
ROBIN HOWARD WPresident & CEOFeb 20Option Exercise7.2133,334240,338342,043Feb 21 08:16 PM
ROBIN HOWARD WPresident & CEOFeb 20Sale43.2033,3341,440,029308,709Feb 21 08:16 PM
ROBIN HOWARD WPresident & CEOFeb 19Option Exercise7.2133,333240,331350,924Feb 21 08:16 PM
Thomsen Jillian B.SVP & Chief Accounting OfficerFeb 19Sale42.391,80876,641166,391Feb 21 08:17 PM
Nicholson JohnSVP & Chief Operating OfficerFeb 19Sale42.393,822162,015170,655Feb 21 08:15 PM
ROBIN HOWARD WPresident & CEOFeb 19Sale42.3342,2151,787,161308,709Feb 21 08:16 PM
Labrucherie Gil MSVP & Chief Financial OfficerFeb 19Sale42.393,592152,265131,702Feb 21 08:14 PM
Hora ManinderSVP Pharma Dev & Mfg OpsFeb 19Sale42.392,386101,14397,143Feb 21 08:13 PM
Doberstein Stephen KSVP & Chief Scientific OfficerFeb 19Sale42.393,310140,31199,374Feb 21 08:13 PM
Thomsen Jillian B.SVP & Chief Accounting OfficerFeb 04Option Exercise10.6916,119172,312184,318Feb 06 07:17 PM
Thomsen Jillian B.SVP & Chief Accounting OfficerFeb 04Sale42.1616,119679,577168,199Feb 06 07:17 PM
Nicholson JohnSVP & Chief Operating OfficerJan 28Option Exercise10.6963,000673,470237,477Jan 30 06:02 PM
Nicholson JohnSVP & Chief Operating OfficerJan 28Sale42.8263,0002,697,660174,477Jan 30 06:02 PM
Thomsen Jillian B.SVP & Chief Accounting OfficerNov 16Sale38.254,016153,612157,249Nov 19 06:15 PM
Nicholson JohnSVP & Chief Operating OfficerNov 16Sale38.255,982228,812174,477Nov 19 06:14 PM
ROBIN HOWARD WPresident & CEONov 16Sale38.2515,326586,220249,141Nov 19 06:14 PM
Hora ManinderSVP Pharma Dev & Mfg OpsNov 16Sale38.254,694179,54681,029Nov 19 06:12 PM
Labrucherie Gil MSVP & Chief Financial OfficerNov 16Sale38.256,515249,199106,544Nov 19 06:13 PM
Doberstein Stephen KSVP & Chief Scientific OfficerNov 16Sale38.254,524173,04378,734Nov 19 06:11 PM
Lingnau LutzDirectorSep 20Sale56.989,000512,82018,450Sep 21 07:32 PM
Ajer Jeffrey RobertDirectorSep 20Sale56.766,750383,13015,750Sep 21 07:29 PM
CHESS ROBERTDirectorSep 19Sale56.814,500255,645269,723Sep 21 07:31 PM
GREER R SCOTTDirectorSep 04Option Exercise5.1410,00051,400140,333Sep 06 07:12 PM
GREER R SCOTTDirectorSep 04Sale67.3910,000673,900130,333Sep 06 07:12 PM